Next-generation DNA sequencing of HEXA: A step in the right direction for carrier screening

Molecular Genetics and Genomic Medicine

Volumn 1, Issue 4, 2013, Pages 260-268

  Hoffman, Jodi D ^a   Greger, Valerie ^b   Strovel, Erin T ^c   Blitzer, Miriam G ^c   Umbarger, Mark A ^b   Kennedy, Caleb ^b   Bishop, Brian ^b   Saunders, Patrick ^b   Porreca, Gregory J ^b   Schienda, Jaclyn ^d   Davie, Jocelyn ^b   Hallam, Stephanie ^b   Towne, Charles ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b Good Start Genetics Inc   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Ethnic based screening; Genetic screening; Hexosaminidase A; Next generation DNA sequencing; Tay Sachs disease

Indexed keywords

EID: 84908299843     PISSN: None     EISSN: 23249269     Source Type: Journal    
DOI: 10.1002/mgg3.37     Document Type: Article

References (40)

1. Adzhubei, I. A., S. Schmidt, L. Peshkin, V. E. Ramensky, A. Gerasimova, P. Bork, et al. 2010. A method and server for predicting damaging missense mutations. Nat. Methods 7:248–249.
2. Akli, S., J. Chelly, J. M. Lacorte, L. Poenaru, and A. Kahn. 1991. Seven novel Tay-Sachs mutations detected by chemical mismatch cleavage of PCR-amplified cDNA fragments. Genomics 11:124–134.
3. Akli, S., J. C. Chomel, J. M. Lacorte, L. Bachner, A. Kahn, and L. Poenaru. 1993. Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients. Hum. Mol. Genet. 2:61–67.
4. Alvarez-Rodriguez, A., B. Triggs-Raine, P. Barros-Nunez, and C. M. Lozano. 2001. A novel HEXA mutation [1393G>A (D465N)] in a Mexican Tay-Sachs disease patient. Hum. Mutat. 17:437.
5. Andermann, E., C. R. Scriver, L. S. Wolfe, L. Dansky, and F. Andermann. 1977. Genetic variants of Tay-Sachs disease: Tay-Sachs disease and Sandhoff’s disease in French Canadians, juvenile Tay-Sachs disease in Lebanese Canadians, and a Tay-Sachs screening program in the French-Canadian population. Prog. Clin. Biol. Res. 18:161–188.
6. Bach, G., J. Tomczak, N. Risch, and J. Ekstein. 2001. Tay-Sachs screening in the Jewish Ashkenazi population: DNA testing is the preferred procedure. Am. J. Med. Genet. 99:70–75.
7. Ben-Yoseph, Y., J. E. Reid, B. Shapiro, and H. L. Nadler. 1985. Diagnosis and carrier detection of Tay-Sachs disease: direct determination of hexosaminidase A using 4-methylumbelliferyl derivatives of beta-N-acetylglucosamine-6-sulfate and beta-N-acetylgalactosamine-6-sulfate. Am. J. Hum. Genet. 37:733–740.
8. Branda, K. J., J. Tomczak, and M. R. Natowicz. 2004. Heterozygosity for Tay-Sachs and Sandhoff diseases in non-Jewish Americans with ancestry from Ireland, Great Britain, or Italy. Genet. Test. 8:174–180.
9. d’Azzo, A., R. L. Proia, E. H. Kolodny, M. M. Kaback, and E. F. Neufeld. 1984. Faulty association of alpha- and beta-subunits in some forms of beta-hexosaminidase A deficiency. J. Biol. Chem. 259:11070–11074.
10. D’Souza, G., C. L. McCann, J. Hedrick, C. Fairley, H. L. Nagel, J. D. Kushner, et al. 2000. Tay-Sachs disease carrier screening: a 21-year experience. Genet. Test. 4:257–263.
11. DeMarchi, J. M., C. T. Caskey, and C. S. Richards. 1996. Population-specific screening by mutation analysis for diseases frequent in Ashkenazi Jews. Hum. Mutat. 8: 116–125.
12. Fernandes, M., F. Kaplan, M. Natowicz, E. Prence, E. Kolodny, M. Kaback, et al. 1992. A new Tay-Sachs disease B1 allele in exon 7 in two compound heterozygotes each with a second novel mutation. Hum. Mol. Genet. 1:759–761.
13. Gort, L., N. de Olano, J. Macias-Vidal, and M. A. Coll. 2012. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients. Gene 506:25–30.
14. Kaback, M., J. Lim-Steele, D. Dabholkar, D. Brown, N. Levy, and K. Zeiger. 1993. Tay-Sachs disease–carrier screening, prenatal diagnosis, and the molecular era. An international perspective, 1970 to 1993. The International TSD Data Collection Network. JAMA 270:2307–2315.
15. Kumar, P., S. Henikoff, and P. C. Ng. 2009. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat. Protoc. 4: 1073–1081.
16. Lazarin, G. A., I. S. Haque, S. Nazareth, K. Iori, A. S. Patterson, J. L. Jacobson, et al. 2013. An empirical estimate of carrier frequencies for 400 + causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet. Med. 15:178–186.
17. Martin, D. C., B. L. Mark, B. L. Triggs-Raine, and M. R. Natowicz. 2007. Evaluation of the risk for Tay-Sachs disease in individuals of French Canadian ancestry living in new England. Clin. Chem. 53:392–398.
18. McDowell, G. A., E. H. Mules, P. Fabacher, E. Shapira, and M. G. Blitzer. 1992. The presence of two different infantile Tay-Sachs disease mutations in a Cajun population. Am. J. Hum. Genet. 51:1071–1077.
19. Monaghan, K. G., G. L. Feldman, G. E. Palomaki, and E. B. Spector. 2008. Technical standards and guidelines for reproductive screening in the Ashkenazi Jewish population. Genet. Med. 10:57–72.
20. Montalvo, A. L., M. Filocamo, K. Vlahovicek, A. Dardis, S. Lualdi, F. Corsolini, et al. 2005. Molecular analysis of the HEXAgene in Italian patients with infantile and late onset Tay-Sachs disease: detection of fourteen novel alleles. Hum. Mutat. 26:282.
21. Myerowitz, R. 1988. Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group. Proc. Natl. Acad. Sci. USA 85:3955–3959.
22. Myerowitz, R., and F. C. Costigan. 1988. The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. J. Biol. Chem. 263:18587–18589.
23. Nakagawa, S., J. Zhan, W. Sun, J. C. Ferreira, S. Keiles, T. Hambuch, et al. 2012. Platelet hexosaminidase A enzyme assay effectively detects carriers missed by targeted DNA mutation analysis. JIMD Rep. 6:1–6.
24. Natowicz, M. R., and E. M. Prence. 1996. Heterozygote screening for Tay-Sachs disease: past successes and future challenges. Curr. Opin. Pediatr. 8:625–9.
25. Navon, R., and R. L. Proia. 1989. The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult form of Tay-Sachs disease. Science 243:1471–1474.
26. O’Brien, J. S., S. Okada, A. Chen, and D. L. Fillerup. 1970. Tay-sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N. Engl. J. Med. 283:15–20.
27. Park, N. J., C. Morgan, R. Sharma, Y. Li, R. M. Lobo, J. B. Redman, et al. 2010. Improving accuracy of Tay Sachs carrier screening of the non-Jewish population: analysis of 34 carriers and six late-onset patients with HEXA enzyme and DNA sequence analysis. Pediatr. Res. 67:217–220.
28. Paw, B. H., S. M. Moskowitz, N. Uhrhammer, N. Wright, M. M. Kaback, and E. F. Neufeld. 1990. Juvenile GM2 gangliosidosis caused by substitution of histidine for arginine at position 499 or 504 of the alpha-subunit of beta-hexosaminidase. J. Biol. Chem. 265:9452–9457.
29. Paw, B. H., L. C. Wood, and E. F. Neufeld. 1991. A third mutation at the CpG dinucleotide of codon 504 and a silent mutation at codon506of the HEXAgene. Am. J. Hum. Genet. 48:1139–1146.
30. Reva, B., Y. Antipin, and C. Sander. 2011. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 39:e118.
31. Rozenberg, R., F. Kok, M. G. Burin, M. C. Sa Miranda, C. Vasques, A. M. Henriques-Souza, et al. 2006. Diagnosis and molecular characterization of non-classic forms of Tay-Sachs disease in Brazil. J. Child Neurol. 21:540–544.
32. Schneider, A., S. Nakagawa, R. Keep, D. Dorsainville, J. Charrow, K. Aleck, et al. 2009. Population-based Tay-Sachs screening among Ashkenazi Jewish young adults in the 21st century: hexosaminidase A enzyme assay is essential for accurate testing. Am. J. Med. Genet. A 149A:2444–2447.
33. Scott, S. A., L. Edelmann, L. Liu, M. Luo, R. J. Desnick, and R. Kornreich. 2010. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum. Mutat. 31:1240–1250.
34. Strom, C. M., N. J. Park, C. Morgan, R. Lobo, B. Crossley, R. Sharma, et al. 2013. Tay-Sachs carrier screening in the genomics age: gene sequencing versus enzyme analysis in non-Jewish individuals. Open J. Genet. 3:61–66.
35. Tanaka, A., L. T. Hoang, Y. Nishi, S. Maniwa, M. Oka, and T. Yamano. 2003. Different attenuated phenotypes of GM2 gangliosidosis variant B in Japanese patients with HEXA mutations at codon 499, and five novel mutations responsible for infantile acute form. J. Hum. Genet. 48:571–574.
36. Triggs-Raine, B. L., B. R. Akerman, J. T. Clarke, and R. A. Gravel. 1991. Sequence of DNA flanking the exons of the HEXA gene, and identification of mutations in Tay-Sachs disease. Am. J. Hum. Genet. 49:1041–1054.
37. Triggs-Raine, B. L., E. H. Mules, M. M. Kaback, J. S. Lim-Steele, C. E. Dowling, B. R. Akerman, et al. 1992. A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening. Am. J. Hum. Genet. 51:793–801.
38. Umbarger, M. A., C. J. Kennedy, P. Saunders, B. Breton, N. Chennagiri, J. Emhoff, et al. 2013. Next-generation carrier screening. Genet. Med. doi: 10.1038/gim.2013.83 (in press).
39. van Bael, M., M. R. Natowicz, J. Tomczak, E. E. Grebner, and E. M. Prence. 1996. Heterozygosity for Tay-Sachs disease in non-Jewish Americans with ancestry from Ireland or Great Britain. J. Med. Genet. 33:829–832.
40. Zampieri, S., A. Montalvo, M. Blanco, I. Zanin, H. Amartino, K. Vlahovicek, et al. 2012. Molecular analysis of HEXA gene in Argentinean patients affected with Tay-Sachs disease: possible common origin of the prevalent c.459 + 5A>G mutation. Gene 499:262–265.